Table 1.
Measles-specific antibodies, variability and persistence after two doses of MMR vaccine administration
| Study | Subjects Number | Years post second vaccination (median., range) | Antibody assay | Antibody titer (GMT, range if available, 95% CI) | Potentially susceptible (%) | Reference |
|---|---|---|---|---|---|---|
| 1. Gans HA et al.; 2001 | 73 (First dose: 6 months) 61 (First dose: 9 months) |
NA NA |
PRN | 128 mIU/mL (74–215) 426 mIU/mL (241–657) |
40% 11% % (≤120 mIU/mL) |
[94] |
| 2. Gans HA et al.; 2004 | 32 (First dose: 6 months) 23 (First dose: 9 months) |
0.5 0.5 |
PRN | 702 mIU/mL (344–1457) 1546 mIU/mL (686–3484) |
14% 10% (≤120 mIU/mL) |
[95] |
| 3. LeBaron CW et al.; 2007 | 312 Kindergarten 309 Middle school |
5.1 (4.2–6.1) 11.2 (10.1–12.5) |
PRN | 641 mIU/mL (NA) 737 mIU/mL (NA) |
4.7% (≤120 mIU/mL) | [96] |
| 4. Davidkin I et al.; 2008 | 85 younger group 6 Older group |
20 | EIA | 760 mIU/mL (75; 8400) 1113 mIU/mL (220; 5900) |
12% (EIA titer ≤200 mIU/mL) | [97] |
| 5. Haralambieva IH et al.; 2011 | 763 school children | 7.4 (5.6; 9.2). | PRMN | 832 mIU/mL (776; 891) | 8.9% (<PRMN titer of 120) | [12] |
| 6. Kakoulidou M et al.; 2013 | 33 | >7 | EIA | 2098 mIU/mL (180; 8783) | NA | [98] |
| 1097 Rochester cohort | 6.6 (5.0, 8.6) | 896 mIU/mL (423; 1744)* | 2.6% | |||
| 7. Poland GA et al.; 2015 | 970 San Diego cohort | 1.2 (0.7, 2.8) | PRMN | 848 mIU/mL (392; 1635)* | 3.7% | Unpublished data |
| 1038 US cohort | 1.8 (1.3, 2.9) | 762 mIU/mL (345; 1505)* | 4.2%(<PRMN titer of 120) |
*
Median (25% and 75% IQR)